Keoxifene
Categoria
Keoxifene Marchi, Keoxifene Analoghi
Keoxifene Marchi miscela
Keoxifene Formula chimica
C28H27NO4S
Keoxifene RX link
http://www.rxlist.com/cgi/generic/raloxif.htm
Keoxifene FDA foglio
Keoxifene DMS (foglio di materiale di sicurezza)
Keoxifene Sintesi di riferimento
CD Jones et al. J. Med. Cem. 27, 1057 (1984)
Keoxifene Peso molecolare
473.584 g/mol
Keoxifene Temperatura di fusione
143-147oC
Keoxifene H2O Solubilita
0,25 mg / L
Keoxifene Stato
Solid
Keoxifene LogP
5.749
Keoxifene Forme di dosaggio
Compressa
Keoxifene Indicazione
Per la prevenzione dell'osteoporosi nelle donne in postmenopausa
Keoxifene Farmacologia
Raloxifene, un modulatore selettivo del recettore dell'estrogeno (SERM) della classe benzotiofene, è simile al tamoxifene in quanto produce estrogeno-simile effetti sul metabolismo osseo e dei lipidi, mentre antagonizzare gli effetti degli estrogeni sul tessuto mammario. Raloxifene riduce il riassorbimento osseo, aumenta la densità minerale ossea (BMD) e riduce l'incidenza di fratture. Il raloxifene è utilizzato nella prevenzione della menopausa l'osteoporosi e il cancro al seno.
Keoxifene Assorbimento
Circa il 60% di una dose orale viene assorbita, ma glucuronoconiugazione presistemica è ampia. La biodisponibilità assoluta del raloxifene è pari a 2,0%
Keoxifene Tossicita
Nessuna informazione disponibile
Keoxifene Informazioni paziente
PATIENT INFORMATION
For safe and effective use of EVISTA, the physician should inform patients about the following:
Patient Immobilization: EVISTA should be discontinued at least 72 hours prior to and during prolonged immobilization
(e.g., post-surgical recovery, prolonged bed rest), and patients should be advised to avoid prolonged restrictions of
movement during travel because of the increased risk of venous thromboembolic events.
Hot flashes or flushes: EVISTA is not effective in reducing hot flashes or flushes associated with estrogen deficiency.
In some asymptomatic patients, hot flashes may occur upon beginning EVISTA therapy.
Other Preventive Measures: Patients should be instructed to take supplemental calcium and vitamin D, if daily dietary
intake is inadequate. Weight-bearing exercise should be considered along with the modification of certain behavioral
factors, such as cigarette smoking, and/or alcohol consumption, if these factors exist.
Physicians should instruct their patients to read the patient package insert before starting therapy with EVISTA and to
re-read it each time the prescription is renewed.
For safe and effective use of EVISTA, the physician should inform patients about the following:
Patient Immobilization: EVISTA should be discontinued at least 72 hours prior to and during prolonged immobilization
(e.g., post-surgical recovery, prolonged bed rest), and patients should be advised to avoid prolonged restrictions of
movement during travel because of the increased risk of venous thromboembolic events.
Hot flashes or flushes: EVISTA is not effective in reducing hot flashes or flushes associated with estrogen deficiency.
In some asymptomatic patients, hot flashes may occur upon beginning EVISTA therapy.
Other Preventive Measures: Patients should be instructed to take supplemental calcium and vitamin D, if daily dietary
intake is inadequate. Weight-bearing exercise should be considered along with the modification of certain behavioral
factors, such as cigarette smoking, and/or alcohol consumption, if these factors exist.
Physicians should instruct their patients to read the patient package insert before starting therapy with EVISTA and to
re-read it each time the prescription is renewed.
Keoxifene Atto interessato organismi
Gli esseri umani e altri mammiferi
